Latest Market Entry News

Iondrive Limited has joined a €3.1 million European battery recycling consortium backed by a German government grant, aiming to establish a closed-loop supply chain using its innovative DES technology.

HyTerra Limited has begun trading on the US OTCQB Venture Market, opening doors to American investors and supporting its strategic expansion in the burgeoning geologic hydrogen sector.

Sarytogan Graphite Limited has obtained a US$2.2 million loan advance from a related party investor to accelerate its Definitive Feasibility Study on the strategically important Sarytogan Graphite Project in Kazakhstan.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

BPH Global Ltd reports a steady increase in Indonesian seaweed sales alongside securing a crucial export licence, setting the stage for international market entry.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Pinnacle Minerals Ltd is fast-tracking its U.S. growth by initiating a listing on the OTCQB Market and appointing key U.S. advisers to boost investor engagement and capital access.

Adveritas Limited has reported a record annualised recurring revenue of $12.2 million for the September 2025 quarter, driven by strong affiliate momentum and initial commercialisation of its Meta integration. The company is advancing its US expansion with a robust trial pipeline and expects significant contract conversions in the coming quarter.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.